ByDavid Prosser
ByDavid Prosser,
Contributor.
Emilia McLaughlin thinks her technology could unlock new drug development
Adverse reactions are a hugely challenging problem for drug developers and biotech companies. A drug that has the potential to help patients with very serious conditions – cancers and auto-immune diseases, for example – proves ineffective because the human immune system identifies it as a foreign body and attacks it. Sometimes this happens with all patients; in other cases, the response is individual. And sometimes, it happens as soon as someone starts taking a drug; or it might happen at a later stage, rendering a treatment ineffective after a period during which it worked well.
